Clinical Trial

Study of Human Bone Marrow Mesenchymal Stem Cells in APAP

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 24, 2025 (before its estimated July 22, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this open-label phase IIa clinical trial study is to evaluate the safety and preliminary efficacy of hBMMSC intravenous treatment in patients with aPAP.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-10-26; most recent amendment 2025-03-19.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-03-19
Trial Details
NCT Number NCT06111846
Lead Sponsor Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.
Collaborators: The First Affiliated Hospital of Guangzhou Medical University
Conditions Autoimmune Pulmonary Alveolar Proteinosis
Enrollment 10 participants
Start Date 2023-12-25
Primary Completion 2025-07-22 (estimated)
Study Completion 2026-08-30 (estimated)
Updated on ClinicalTrials.gov 2025-03-24